Stockscreener 앱 받기
0.45%
전일 마감가:
$22.04
열려 있는:
$22.15
하루 거래량:
52.22M
Relative Volume:
1.14
시가총액:
$125.45B
수익:
$63.63B
순이익/손실:
$8.03B
주가수익비율:
15.70
EPS:
1.41
순현금흐름:
$9.84B
1주 성능:
+2.55%
1개월 성능:
-15.01%
6개월 성능:
-24.36%
1년 성능:
-12.90%
1일 변동 폭
$22.10
$22.55
1주일 범위
$21.28
$22.93
52주 변동 폭
$20.91
$31.54
화이자 Stock (PFE) Company Profile
명칭
Pfizer Inc
전화
(212) 733-2323
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
PFE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
22.14 | 125.45B | 63.63B | 8.03B | 9.84B | 1.41 |
|
LLY
Lilly Eli Co
|
839.96 | 677.40B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
157.47 | 371.98B | 89.33B | 21.81B | 18.06B | 8.99 |
|
ABBV
Abbvie Inc
|
172.99 | 316.82B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
58.08 | 293.24B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.86 | 216.19B | 51.72B | 11.94B | 13.81B | 5.88 |
화이자 Stock (PFE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-25 | 재개 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | 다운그레이드 | Argus | Buy → Hold |
| 2024-02-23 | 개시 | Guggenheim | Buy |
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-10-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-17 | 재확인 | JP Morgan | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-06-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-20 | 재확인 | Cowen | Outperform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-13 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-12-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 재개 | Goldman | Neutral |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-10-12 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-16 | 개시 | SVB Leerink | Mkt Perform |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-27 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-07-30 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 재개 | Morgan Stanley | Overweight |
| 2019-02-20 | 재개 | Citigroup | Neutral |
| 2019-01-31 | 업그레이드 | Argus | Hold → Buy |
| 2019-01-31 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2018-12-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-01 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
모두보기
화이자 주식(PFE)의 최신 뉴스
Xylose Absorption Test Market Is Booming Worldwide 2025-2032 | Pfizer Inc., Bristol-Myers Squibb Company - openPR.com
Pfizer Abandons Its Leading Weight Loss Candidate. Should You Sell the Stock? - Nasdaq
Huntington's Disease Treatment Market to Hit $2.03 Billion by 2033, Driven by Cutting-Edge Therapies - GlobeNewswire Inc.
Lilly Soars As Study Shows Weight-Loss Pill to Pass Ozempic - Yahoo Finance
Pfizer (PFE) Laps the Stock Market: Here's Why - Yahoo Finance
Post-Pfizer dropout, Lilly Achieves GLP-1 win in phase III - BioWorld MedTech
US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years - Benzinga
Is Pfizer Inc. (PFE) the Best Large-Cap Value Stock to Buy as the Recession Hits? - Insider Monkey
GSK Zantac Appeal Gets Tough Questions From Some US Judges - Bloomberg
U.S. Unfractionated Heparin Market Is Booming Worldwide 2025-2032 | Pfizer, Inc., Sagent Pharmaceuticals - openPR.com
Neuroendocrine Tumor Treatment Market Is Booming Worldwide | - openPR.com
Viking Therapeutics (VKTX) Shares Surge on Pfizer's Decision - GuruFocus
Pfizer, GSK to gain as CDC ACIP votes for RSV shots (NYSE:PFE) - Seeking Alpha
It Looks Like Pfizer Inc.'s (NYSE:PFE) CEO May Expect Their Salary To Be Put Under The Microscope - simplywall.st
Henlius In David Versus Goliath Race With Pfizer For First PD-L1 ADC - insights.citeline.com
Pfizer: Risks Priced In, Buy The Exceptional Valuation And Yield - Seeking Alpha
Lobbying Update: $20,000 of PFIZER INC lobbying was just disclosed - Nasdaq
Pfizer Says US CDC Panel Votes to Expand Recommendation for RSV Vaccine - MarketScreener
Pfizer gets ACIP backing as it votes to expand RSV vaccine recommendation - Seeking Alpha
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO - Business Wire
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease - Yahoo Finance
Pfizer: Tasty 7% Yield (NYSE:PFE) - Seeking Alpha
What You Need to Know Ahead of Pfizer's Earnings Release - Nasdaq
Empyema Market Deep Research Report with Forecast by 2032 | Pfizer Inc.,Merck & Co., Inc.,GlaxoSmithKline plc - openPR.com
Stomach Cancer Drugs Market Witness Significant Growth by 2025-2032 | Pfizer Inc., Eli Lilly and Company - openPR.com
Tariff Turmoil, FDA’s Future, Pfizer’s Obesity Setback and CEO Salaries Revealed - BioSpace
Neuropathic Pain Market Detailed In New Research Report 2025 | - openPR.com
Why Pfizer Stock Topped the Market on Tuesday - Yahoo Finance
Will Pfizer approach Viking Therapeutics with a buyout proposal? - TradingView
Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study - Benzinga
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes (NASDAQ:VKTX) - Seeking Alpha
Pfizer Halts Obesity Pill Development Amid Safety Concerns - Zacks Investment Research
Bernstein reiterates Pfizer stock with $30 target post-drug axe - Investing.com
Bernstein reiterates Pfizer stock with $30 target post-drug axe By Investing.com - Investing.com India
TD Cowen Remains a Hold on Pfizer (PFE) - The Globe and Mail
Pfizer (PFE) Gets a Hold from Bernstein - The Globe and Mail
BofA keeps Neutral on Pfizer after danuglipron failure as core thesis unchanged - Yahoo Finance
Pfizer Ends Testing of Obesity Pill After Possible Liver Injury - El Paso Inc.
Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill - Yahoo Finance
What You Need To Know Ahead Of Pfizer's Earnings Release - Barchart.com
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? - MSN
Pfizer scraps weight loss candidate after trial setback: What it means for the future of oral obesity drugs - munsifdaily.com
Pfizer Halts Oral GLP-1 Drug Danuglipron Development Amid Liver Safety Concerns - geneonline.com
Pfizer (PFE) Abandons Obesity Drug Trial Due to Safety Concerns - GuruFocus
Pfizer (PFE) Halts Trial of GLP-1 Pill Due to Safety Concerns - GuruFocus
Why Pfizer scrapped obesity pill development: Weight-loss drug market shares explored - financialexpress.com
Pfizer Ends Development of Its Obesity Pill - Time Magazine
Pfizer ends development of potential pill obesity treatment - CNN
Pfizer to no longer develop weight loss pill - The San Joaquin Valley Sun
Pfizer hits setback in obesity drug race as GLP-1 trial halts - Yahoo Finance
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
화이자 (PFE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.67%
0.32%
자본화:
|
볼륨(24시간):